Nucleation announces its investment in Aalo Atomic’s Series A with Fund I
Aalo Atomics is a group that recognizes the importance of being one of the first to market with an NRC-approved reactor design that can be shipped to customers. They have not only hit the ground running but they have adopted an approach that leverages publicly-funded DOE design and development work that will help to expedite the NRC’s approval of the Aalo-1, which will be modeled upon the DOE’s MARVEL reactor that is being built now and which will be producing test data within the next few years.
MARVEL, a sodium-potassium-cooled micro-reactor and the first Gen IV design to come out of the national labs in over thirty years, is being built now with completion expected in 2025. The Idaho National Laboratory (INL) expects to complete construction, load fuel in 2026 and begin testing this very pared down design inside the Transient Reactor Test (TREAT) facility in 2027. Aalo will be well-situated to access the publicly available test data produced by this DOE research program, to provide it with a true competitive advantage when applying for their own NRC license for their comparable design.
We expect many more good things to come from this dynamic young team. Read more about Aalo and their Series A financing on their website, or from Bloomberg or Politico Pro. Follow some additional milestones with reporting from Sonal Patel, of Power Magazine, on Aalo negotiating its first PPA.
(Note: Investors who have subscribed to Nucleation’s Fund I Q3-2024 will get participation in this investment.)